ANN ARBOR, Mich., Feb. 8, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that an abstract on the Company’s pivotal clinical trial of its zinc and cysteine-based product candidate being evaluated in patients with Alzheimer’s disease and mild cognitive impairment has been accepted for presentation at the 2011 American Academy of Neurology Annual Meeting in April. The abstract will provide top line clinical trial results, as well as the rationale and design of the pivotal study.
Diana Pollock, M.D., Lead Principal Investigator of the trial at Morton Plant Neuroscience Institute on the campus of Morton Plant Hospital, is the first author on the abstract titled “Clinical Trial Results of the First Controlled Clinical Trial of Zinc-Based Therapy for Alzheimer’s Disease and Mild Cognitive Impairment.” The poster presentation will be held from 2:00 to 6:30 p.m. on April 14, 2011 at the Hawaii Convention Center in Honolulu, Hawaii. Due to conference restrictions with regard to the embargo policy relating to clinical trial results, Adeona plans to present the results of its pivotal clinical trial during this conference and distribute a concurrent press release.
Adeona also announced that “reaZin” has been adopted as the new trademark for its zinc and cysteine-based oral tablet currently under development as a prescription medical food for the dietary management of Alzheimer’s disease and mild cognitive impairment. Previously, Adeona’s zinc and cysteine-based product candidate was called Zinthionein.
reaZin was selected as the new trademark as it is a homophone to the word reason, a high level cognitive function affected by Alzheimer’s disease that Adeona’s product candidate seeks to address. In addition, the “Zin” root is suggestive of the product’s zinc origin, one of the two major constituents of the proprietary, gastro-retentive, sustained-release tablet. The new branding for reaZin will be unveiled at the Company’s Investor Day on Zinc Deficiency in Alzheimer’s Disease, taking place this afternoon in Ann Arbor, MI.
“The large gathering of neurologists at the American Academy of Neurology’s 63rd Annual Meeting is an excellent scientific venue to present the pivotal clinical study results of our zinc and cysteine-based prescription medical food product candidate for Alzheimer’s disease and mild cognitive impairment,” stated James S. Kuo, M.D., M.B.A., Adeona’s Chairman and CEO. “We are delighted that our clinical investigator has been accepted to present this important clinical data.”
About the American Academy of Neurology
The American Academy of Neurology, an association of more than 22,500 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease, and multiple sclerosis. For more information about the American Academy of Neurology, visit http://www.aan.com. For more information about the American Academy of Neurology’s 63rd Annual Meeting set for April 9 - 16, 2011, at the Hawaii Convention Center, visit http://www.aan.com/go/am.
About the Pivotal Clinical Study Evaluating reaZin
reaZin (zinc cysteine), formerly named Zinthionein, is a proprietary oral tablet formulation of zinc and cysteine, an amino acid with potent anti-oxidant properties. Adeona is developing this product candidate for the dietary management of Alzheimer’s disease and mild cognitive impairment as a prescription medical food. All 60 patients are enrolled in the clinical study evaluating reaZin. In this randomized, double-blind, placebo-controlled study, patients are assessed 3 and 6 months after they begin the once-daily oral treatment or matching placebo. These 60 patients should complete their 6 month treatment by the end of March 2011. If successful, Adeona expects to make its reaZin product commercially available as a prescription medical food for patients suffering from Alzheimer’s disease and mild cognitive impairment.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company’s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer’s disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona’s website at www.adeonapharma.com.
This release includes forward-looking statements on Adeona’s current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical study and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona’s forward-looking statements include, among others, the availability of financial and other resources and the allocation of resources among different potential uses, a failure of our clinical trials to be completed on time or to achieve desired results, a failure of the new branding to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona’s report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.
